Stock TARA PROTARA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
3.1 USD +5.98% Intraday chart for Protara Therapeutics, Inc. +3.33% +65.32%
Apr. 22 Oppenheimer Adjusts Protara Therapeutics Price Target to $30 From $26 MT
Apr. 05 Protara Therapeutics, Inc Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Protara Therapeutics, Inc Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
CI
Protara Therapeutics, Inc. Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
CI
Protara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Protara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Proteon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Stock Futures -2-
DJ
Protara Therapeutics, Inc. Announces Presentation of Additional Encouraging Data from Phase 1A Advanced-1 Trial of Tara-002 in Nmibc At the 24Th Annual Meeting of the Society of Urologic Oncology
CI
Protara Therapeutics Q3 Loss Widens; Files for $300 Million Mixed-Securities Shelf Registration
MT
Protara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Proteon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Protara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Proteon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
CI
Protara Therapeutics, Inc. Announces Positive Preliminary Data from Advanced-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development
CI
Protara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Protara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
Protara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Protara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TARA Stock
  4. News Protara Therapeutics, Inc.
  5. Highlights